Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.

Fiche publication

Date publication

mai 2024

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOREL Christian , Dr ETIENNE-SELLOUM Nelly , Pr VELTEN Michel , Dr ZANETTA Sylvie , Dr BURGY Mickaël

Tous les auteurs :
Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, Alfonsi M, Janoray G, Chatellier T, Garcia-Ramirez M, Gherga E, Hammoud Y, Burgy M, Etienne-Selloum N, Pechery A, Girard-Calais MH, Velten M, Pignon JP, Wanneveich M, Bourhis J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38768714

Résumé

Chemoradiotherapy with high-dose cisplatin (HD-Cis: 100 mg/m q3w for three cycles) is the standard of care (SOC) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Cumulative delivered dose of cisplatin is prognostic of survival, even beyond 200 mg/m but high toxicity compromises its delivery.